Funfschilling, U. et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 485, 517–521 (2012).
Saab, A. S., Tzvetanova, I. D. & Nave, K. A. The role of myelin and oligodendrocytes in axonal energy metabolism. Curr. Opin. Neurobiol. 23, 1065–1072 (2013).
Young, K. M. et al. Oligodendrocyte dynamics in the healthy adult CNS: evidence for myelin remodeling. Neuron 77, 873–885 (2013).
Hughes, E. G., Orthmann-Murphy, J. L., Langseth, A. J. & Bergles, D. E. Myelin remodeling through experience-dependent oligodendrogenesis in the adult somatosensory cortex. Nat. Neurosci. 21, 696–706 (2018).
Hill, R. A., Li, A. M. & Grutzendler, J. Lifelong cortical myelin plasticity and age-related degeneration in the live mammalian brain. Nat. Neurosci. 21, 683–695 (2018).
Kang, S. H., Fukaya, M., Yang, J. K., Rothstein, J. D. & Bergles, D. E. NG2+ CNS glial progenitors remain committed to the oligodendrocyte lineage in postnatal life and following neurodegeneration. Neuron 68, 668–681 (2010).
Yeung, M. S. et al. Dynamics of oligodendrocyte generation and myelination in the human brain. Cell 159, 766–774 (2014).
Hess, K. et al. Lesion stage-dependent causes for impaired remyelination in MS. Acta Neuropathol. 140, 359–375 (2020). This paper identified oligodendrocyte lineage cell responses associated with remyelination failure in multiple sclerosis lesions at different stages of damage and repair, identifying oligodendrocyte loss as a feature of poor remyelination in chronic lesions.
Prineas, J. W. & Parratt, J. D. Oligodendrocytes and the early multiple sclerosis lesion. Ann. Neurol. 72, 18–31 (2012).
Rodriguez, M., Scheithauer, B. W., Forbes, G. & Kelly, P. J. Oligodendrocyte injury is an early event in lesions of multiple sclerosis. Mayo Clin. Proc. 68, 627–636 (1993).
Ryu, J. K. et al. Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat. Immunol. 19, 1212–1223 (2018).
Liddelow, S. A. et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541, 481–487 (2017).
Rothhammer, V. et al. Microglial control of astrocytes in response to microbial metabolites. Nature 557, 724–728 (2018).
Wheeler, M. A. et al. MAFG-driven astrocytes promote CNS inflammation. Nature 578, 593–599 (2020).
Wheeler, M. A., Rothhammer, V. & Quintana, F. J. Control of immune-mediated pathology via the aryl hydrocarbon receptor. J. Biol. Chem. 292, 12383–12389 (2017).
Lampron, A. et al. Inefficient clearance of myelin debris by microglia impairs remyelinating processes. J. Exp. Med. 212, 481–495 (2015).
Kotter, M. R., Li, W. W., Zhao, C. & Franklin, R. J. Myelin impairs CNS remyelination by inhibiting oligodendrocyte precursor cell differentiation. J. Neurosci. 26, 328–332 (2006).
Healy, L. M. et al. MerTK is a functional regulator of myelin phagocytosis by human myeloid cells. J. Immunol. 196, 3375–3384 (2016).
Cui, Q. L. et al. Sublethal oligodendrocyte injury: a reversible condition in multiple sclerosis? Ann. Neurol. 81, 811–824 (2017).
Hoffmann, A. et al. Oligodendroglial alpha-synucleinopathy-driven neuroinflammation in multiple system atrophy. Brain Pathol. 29, 380–396 (2019).
Meissner, W. G. et al. Multiple system atrophy: recent developments and future perspectives. Mov. Disord. 34, 1629–1642 (2019).
Bugiani, M., Vuong, C., Breur, M. & van der Knaap, M. S. Vanishing white matter: a leukodystrophy due to astrocytic dysfunction. Brain Pathol. 28, 408–421 (2018).
Azevedo, C. et al. Parkinson’s disease and multiple system atrophy patient iPSC-derived oligodendrocytes exhibit alpha-synuclein-induced changes in maturation and immune reactive properties. Proc. Natl Acad. Sci. USA 119, e2111405119 (2022).
Nasrabady, S. E., Rizvi, B., Goldman, J. E. & Brickman, A. M. White matter changes in Alzheimer’s disease: a focus on myelin and oligodendrocytes. Acta Neuropathol. Commun. 6, 22 (2018).
Eluvathingal, T. J. et al. Abnormal brain connectivity in children after early severe socioemotional deprivation: a diffusion tensor imaging study. Pediatrics 117, 2093–2100 (2006).
Makinodan, M., Rosen, K. M., Ito, S. & Corfas, G. A critical period for social experience-dependent oligodendrocyte maturation and myelination. Science 337, 1357–1360 (2012).
Dietz, A. G., Goldman, S. A. & Nedergaard, M. Glial cells in schizophrenia: a unified hypothesis. Lancet Psychiatry 7, 272–281 (2020).
Raabe, F. J. et al. Oligodendrocytes as a new therapeutic target in schizophrenia: from histopathological findings to neuron-oligodendrocyte interaction. Cells 8, https://doi.org/10.3390/cells8121496 (2019).
Galvez-Contreras, A. Y., Zarate-Lopez, D., Torres-Chavez, A. L. & Gonzalez-Perez, O. Role of oligodendrocytes and myelin in the pathophysiology of autism spectrum disorder. Brain Sci. 10, https://doi.org/10.3390/brainsci10120951 (2020).
van Tilborg, E. et al. Impaired oligodendrocyte maturation in preterm infants: Potential therapeutic targets. Prog. Neurobiol. 136, 28–49 (2016).
Cui, Q. L. et al. Oligodendrocyte progenitor cell susceptibility to injury in multiple sclerosis. Am. J. Pathol. 183, 516–525 (2013).
Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25, 486–541 (2018).
Edinger, A. L. & Thompson, C. B. Death by design: apoptosis, necrosis and autophagy. Curr. Opin. Cell Biol. 16, 663–669 (2004).
Barnett, M. H. & Prineas, J. W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55, 458–468 (2004).
Lucchinetti, C. F., Bruck, W. & Lassmann, H. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann. Neurol. 56, 308 (2004).
Casaccia, P. & Boddeke, E. Foreword. Glia 68, 1551–1553 (2020).
Saikali, P. et al. NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis. J. Neurosci. 27, 1220–1228 (2007).
Zaguia, F. et al. Cytotoxic NKG2C+ CD4 T cells target oligodendrocytes in multiple sclerosis. J. Immunol. 190, 2510–2518 (2013).
Larochelle, C. et al. Pro-inflammatory T helper 17 directly harms oligodendrocytes in neuroinflammation. Proc. Natl Acad. Sci. USA 118, https://doi.org/10.1073/pnas.2025813118 (2021). This study demonstrated that direct contact between Th17 T lymphocytes and oligodendrocytes induces oligodendrocyte stress, reduces myelinaton, and increases cell death.
Jamann, H. et al. Contact-dependent granzyme B-mediated cytotoxicity of Th17-polarized cells toward human oligodendrocytes. Front. Immunol. 13, https://doi.org/10.3389/fimmu.2022.850616 (2022).
Ludwin, S. K. & Johnson, E. S. Evidence for a “dying-back” gliopathy in demyelinating disease. Ann. Neurol. 9, 301–305 (1981).
Pernin, F. et al. Diverse injury responses of human oligodendrocyte to mediators implicated in multiple sclerosis. Brain https://doi.org/10.1093/brain/awac075 (2022). This study identified the stress responses in primary human oligodendrocytes following exposure to injury mediators, revealing mechanisms by which oligodendrocyte process retraction (and therefore demyelination) may occur.
Kast, D. J. & Dominguez, R. The Cytoskeleton-Autophagy Connection. Curr. Biol. 27, R318–R326 (2017).
Yang, L. et al. Raf-1/CK2 and RhoA/ROCK signaling promote TNF-alpha-mediated endothelial apoptosis via regulating vimentin cytoskeleton. Toxicology 389, 74–84 (2017).
Wosik, K. et al. Oligodendrocyte injury in multiple sclerosis: a role for p53. J. Neurochem. 85, 635–644 (2003).
Nicaise, A. M. et al. Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis. Proc. Natl Acad. Sci. USA 116, 9030–9039 (2019).
Absinta, M. et al. A lymphocyte-microglia-astrocyte axis in chronic active multiple sclerosis. Nature 597, 709–714 (2021).
Prineas, J. W. et al. Immunopathology of secondary-progressive multiple sclerosis. Ann. Neurol. 50, 646–657 (2001).
Dhuriya, Y. K. & Sharma, D. Necroptosis: a regulated inflammatory mode of cell death. J. Neuroinflammation 15, 199 (2018).
Ofengeim, D. et al. Activation of necroptosis in multiple sclerosis. Cell Rep. 10, 1836–1849 (2015). This study revealed that oligodendrocyte cell death via controlled necrosis, termed necroptosis, is a feature of demyelination in multiple sclerosis.
Lloyd, A. F. et al. Central nervous system regeneration is driven by microglia necroptosis and repopulation. Nat. Neurosci. 22, 1046–1052 (2019).
Zhang, S. et al. RIP1 kinase inhibitor halts the progression of an immune-induced demyelination disease at the stage of monocyte elevation. Proc. Natl Acad. Sci. USA 116, 5675–5680 (2019).
Zelic, M. et al. RIPK1 activation mediates neuroinflammation and disease progression in multiple sclerosis. Cell Rep. 35, 109112 (2021).
Jurewicz, A. et al. Tumour necrosis factor-induced death of adult human oligodendrocytes is mediated by apoptosis inducing factor. Brain 128, 2675–2688 (2005).
McKenzie, B. A. et al. Caspase-1 inhibition prevents glial inflammasome activation and pyroptosis in models of multiple sclerosis. Proc. Natl Acad. Sci. USA 115, E6065–E6074 (2018).
Hou, J. et al. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat. Cell Biol. 22, 1264–1275 (2020).
Mahad, D. H., Trapp, B. D. & Lassmann, H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 14, 183–193 (2015).
Lassmann, H. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J. Neurol. Sci. 206, 187–191 (2003).
Lassmann, H. & van Horssen, J. Oxidative stress and its impact on neurons and glia in multiple sclerosis lesions. Biochim Biophys. Acta 1862, 506–510 (2016).
Trapp, B. D. & Stys, P. K. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 8, 280–291 (2009).
D’Haeseleer, M. et al. Cerebral hypoperfusion: a new pathophysiologic concept in multiple sclerosis. J. Cereb. Blood Flow. Metab. 35, 1406–1410 (2015).
Witte, M. E., Mahad, D. J., Lassmann, H. & van Horssen, J. Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis. Trends Mol. Med. 20, 179–187 (2014).
Davies, A. L. et al. Neurological deficits caused by tissue hypoxia in neuroinflammatory disease. Ann. Neurol. 74, 815–825 (2013).
Desai, R. A. et al. Cause and prevention of demyelination in a model multiple sclerosis lesion. Ann. Neurol. 79, 591–604 (2016).
Fernandes, M. G. F. et al. Age-related injury responses of human oligodendrocytes to metabolic insults: link to BCL-2 and autophagy pathways. Commun. Biol. 4, 20 (2021).
Liu, Y. et al. Autosis is a Na+,K+-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. Proc. Natl Acad. Sci. USA 110, 20364–20371 (2013).
Maiuri, M. C., Zalckvar, E., Kimchi, A. & Kroemer, G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 8, 741–752 (2007).
Bonapace, L. et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J. Clin. Invest. 120, 1310–1323 (2010).
Forte, M. et al. Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Proc. Natl Acad. Sci. USA 104, 7558–7563 (2007).
Jhelum, P. et al. Ferroptosis mediates cuprizone-induced loss of oligodendrocytes and demyelination. J. Neurosci. 40, 9327–9341 (2020).
Jakel, S. et al. Altered human oligodendrocyte heterogeneity in multiple sclerosis. Nature 566, 543–547 (2019). This was the first study to demonstrate human oligodendrocyte transcriptional heterogeneity in health and in multiple sclerosis, showing a shift in mature oligodendrocyte subpopulations with disease.
Falcao, A. M. et al. Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis. Nat. Med. 24, 1837–1844 (2018).
Seeker, L. A. et al. Marked regional glial heterogeneity in the human white matter of the central nervous system. Preprint at bioRxiv https://doi.org/10.1101/2022.03.22.485367 (2022).
Bechler, M. E., Byrne, L. & Ffrench-Constant, C. CNS myelin sheath lengths are an intrinsic property of oligodendrocytes. Curr. Biol. 25, 2411–2416 (2015).
Vigano, F., Mobius, W., Gotz, M. & Dimou, L. Transplantation reveals regional differences in oligodendrocyte differentiation in the adult brain. Nat. Neurosci. 16, 1370–1372 (2013).
Bai, C. B. et al. A mouse model for testing remyelinating therapies. Exp. Neurol. 283, 330–340 (2016).
Gudi, V. et al. Regional differences between grey and white matter in cuprizone induced demyelination. Brain Res. 1283, 127–138 (2009).
Strijbis, E. M. M., Kooi, E. J., van der Valk, P. & Geurts, J. J. G. Cortical remyelination is heterogeneous in multiple sclerosis. J. Neuropathol. Exp. Neurol. 76, 390–401 (2017).
Chang, A. et al. Cortical remyelination: a new target for repair therapies in multiple sclerosis. Ann. Neurol. 72, 918–926 (2012).
Albert, M., Antel, J., Bruck, W. & Stadelmann, C. Extensive cortical remyelination in patients with chronic multiple sclerosis. Brain Pathol. 17, 129–138 (2007).
Szuchet, S. et al. The genetic signature of perineuronal oligodendrocytes reveals their unique phenotype. Eur. J. Neurosci. 34, 1906–1922 (2011).
Mathys, H. et al. Single-cell transcriptomic analysis of Alzheimer’s disease. Nature 570, 332–337 (2019). This study identified changes in the oligodendrocyte lineage in Alzheimer’s disease, showing populations shifts in disease, some of which correlated with cognitive impairment, and were sex-specific.
Sadick, J. S. et al. Astrocytes and oligodendrocytes undergo subtype-specific transcriptional changes in Alzheimer’s disease. Neuron https://doi.org/10.1016/j.neuron.2022.03.008 (2022).
Macnair, W. et al. Single nuclei RNAseq stratifies multiple sclerosis patients into three distinct white matter glia responses. bioRxiv https://doi.org/10.1101/2022.04.06.487263 (2022).
Ladiwala, U., Li, H., Antel, J. P. & Nalbantoglu, J. p53 induction by tumor necrosis factor-alpha and involvement of p53 in cell death of human oligodendrocytes. J. Neurochem. 73, 605–611 (1999).
Williamson, J. M. & Lyons, D. A. Myelin dynamics throughout life: an ever-changing landscape. Front. Cell Neurosci. 12, 424 (2018).
Luo, J. X. X. et al. Human oligodendrocyte myelination potential; relation to age and differentiation. Ann. Neurol. 91, 178–191 (2022).
Wang, F. et al. Myelin degeneration and diminished myelin renewal contribute to age-related deficits in memory. Nat. Neurosci. 23, 481–486 (2020).
Chen, J. F. et al. Enhancing myelin renewal reverses cognitive dysfunction in a murine model of Alzheimer’s disease. Neuron 109, 2292–2307.e2295 (2021).
Xie, F., Liang, P., Fu, H., Zhang, J. C. & Chen, J. Effects of normal aging on myelin sheath ultrastructures in the somatic sensorimotor system of rats. Mol. Med. Rep. 10, 459–466 (2014).
Peters, A., Sethares, C. & Killiany, R. J. Effects of age on the thickness of myelin sheaths in monkey primary visual cortex. J. Comp. Neurol. 435, 241–248 (2001).
Peters, A. & Sethares, C. Aging and the myelinated fibers in prefrontal cortex and corpus callosum of the monkey. J. Comp. Neurol. 442, 277–291 (2002).
Call, C. L. et al. Oligodendrocytes form paranodal bridges that generate chains of myelin sheaths that are vulnerable to degeneration with age. Preprint at bioRxiv https://doi.org/10.1101/2022.02.16.480718 (2022). This study revealed anovel mechanism of myelination of distal axons by oligodendrocytes, by creatingbridges between myelin internodes; these are particularly vulnerable todegeneration with ageing relative to internodes stemming from theoligodendrocyte cell body.
Neumann, B., Segel, M., Chalut, K. J. & Franklin, R. J. Remyelination and ageing: reversing the ravages of time. Mult. Scler. 25, 1835–1841 (2019).
Shen, S. et al. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat. Neurosci. 11, 1024–1034 (2008).
Ximerakis, M. et al. Single-cell transcriptomic profiling of the aging mouse brain. Nat. Neurosci. 22, 1696–1708 (2019).
Dulken, B. W. et al. Single-cell analysis reveals T cell infiltration in old neurogenic niches. Nature 571, 205–210 (2019).
Yaqubi, M. et al. Regional and age-related diversity of human mature oligodendrocytes. Glia 70, 1938–1949 (2022).
Kirby, L. et al. Oligodendrocyte precursor cells present antigen and are cytotoxic targets in inflammatory demyelination. Nat. Commun. 10, 3887 (2019).
Rone, M. B. et al. Oligodendrogliopathy in multiple sclerosis: low glycolytic metabolic rate promotes oligodendrocyte survival. J. Neurosci. 36, 4698–4707 (2016).
Neumann, B. et al. Metformin restores CNS remyelination capacity by rejuvenating aged stem cells. Cell Stem Cell 25, 473–485 e478 (2019).
Saher, G. et al. High cholesterol level is essential for myelin membrane growth. Nat. Neurosci. 8, 468–475 (2005).
Voskuhl, R. R. et al. Gene expression in oligodendrocytes during remyelination reveals cholesterol homeostasis as a therapeutic target in multiple sclerosis. Proc. Natl Acad. Sci. USA 116, 10130–10139 (2019).
Dimas, P. et al. CNS myelination and remyelination depend on fatty acid synthesis by oligodendrocytes. Elife 8, https://doi.org/10.7554/eLife.44702 (2019).
Camargo, N. et al. Oligodendroglial myelination requires astrocyte-derived lipids. PLoS Biol. 15, e1002605 (2017).
Camargo, N. et al. High-fat diet ameliorates neurological deficits caused by defective astrocyte lipid metabolism. FASEB J. 26, 4302–4315 (2012).
Montani, L. Lipids in regulating oligodendrocyte structure and function. Semin Cell Dev. Biol. 112, 114–122 (2021).
Decker, L., Baron, W. & Ffrench-Constant, C. Lipid rafts: microenvironments for integrin-growth factor interactions in neural development. Biochem Soc. Trans. 32, 426–430 (2004).
Hubler, Z. et al. Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature 560, 372–376 (2018).
Berghoff, S. A. et al. Microglia facilitate repair of demyelinated lesions via post-squalene sterol synthesis. Nat. Neurosci. 24, 47–60 (2021).
Martin, E. et al. Teriflunomide promotes oligodendroglial 8,9-unsaturated sterol accumulation and CNS remyelination. Neurol. Neuroimmunol. Neuroinflamm. 8, https://doi.org/10.1212/NXI.0000000000001091 (2021).
Hubler, Z. et al. Modulation of lanosterol synthase drives 24,25-epoxysterol synthesis and oligodendrocyte formation. Cell Chem. Biol. 28, 866–875.e865 (2021).
Sax, J. L., Hubler, Z., Allimuthu, D. & Adams, D. J. Screening reveals sterol derivatives with pro-differentiation, pro-survival, or potent cytotoxic effects on oligodendrocyte progenitor cells. ACS Chem. Biol. 16, 1288–1297 (2021).
Lombardi, M. et al. Detrimental and protective action of microglial extracellular vesicles on myelin lesions: astrocyte involvement in remyelination failure. Acta Neuropathol. 138, 987–1012 (2019).
Penkert, H. et al. Proteomic and lipidomic profiling of demyelinating lesions identifies fatty acids as modulators in lesion recovery. Cell Rep. 37, 109898 (2021).
Guttenplan, K. A. et al. Neurotoxic reactive astrocytes induce cell death via saturated lipids. Nature 599, 102–107 (2021).
Badreddine, A. et al. Argan oil-mediated attenuation of organelle dysfunction, oxidative stress and cell death induced by 7-ketocholesterol in murine oligodendrocytes 158N. Int. J. Mol. Sci. 18, https://doi.org/10.3390/ijms18102220 (2017).
Dong, Y. et al. Oxidized phosphatidylcholines found in multiple sclerosis lesions mediate neurodegeneration and are neutralized by microglia. Nat. Neurosci. 24, 489–503 (2021).
Itoh, N. et al. Cell-specific and region-specific transcriptomics in the multiple sclerosis model: focus on astrocytes. Proc. Natl Acad. Sci. USA 115, E302–E309 (2018).
Marcos, J., Shackleton, C. H., Buddhikot, M. M., Porter, F. D. & Watson, G. L. Cholesterol biosynthesis from birth to adulthood in a mouse model for 7-dehydrosterol reductase deficiency (Smith-Lemli-Opitz syndrome). Steroids 72, 802–808 (2007).
Dang Do, A. N., Baker, E. H., Warren, K. E., Bianconi, S. E. & Porter, F. D. Spontaneously regressing brain lesions in Smith-Lemli-Opitz syndrome. Am. J. Med. Genet. A 176, 386–390 (2018).
Stumpf, S. K. et al. Ketogenic diet ameliorates axonal defects and promotes myelination in Pelizaeus-Merzbacher disease. Acta Neuropathol. 138, 147–161 (2019).
Osorio, M. J. & Goldman, S. A. Neurogenetics of Pelizaeus-Merzbacher disease. Handb. Clin. Neurol. 148, 701–722 (2018).
Simons, M. et al. Overexpression of the myelin proteolipid protein leads to accumulation of cholesterol and proteolipid protein in endosomes/lysosomes: implications for Pelizaeus-Merzbacher disease. J. Cell Biol. 157, 327–336 (2002).
Laukka, J. J., Kamholz, J., Bessert, D. & Skoff, R. P. Novel pathologic findings in patients with Pelizaeus-Merzbacher disease. Neurosci. Lett. 627, 222–232 (2016).
Davies-Thompson, J., Vavasour, I., Scheel, M., Rauscher, A. & Barton, J. J. Reduced myelin water in the white matter tracts of patients with niemann-pick disease type C. Am. J. Neuroradiol. 37, 1487–1489 (2016).
Yang, F. et al. Proteomics of the corpus callosum to identify novel factors involved in hypomyelinated Niemann-Pick Type C disease mice. Mol. Brain 12, 17 (2019).
Vanier, M. T. Niemann-Pick disease type C. Orphanet J. Rare Dis. 5, 16 (2010).
Chang, C. C. et al. Multi-parametric neuroimaging evaluation of cerebrotendinous xanthomatosis and its correlation with neuropsychological presentations. BMC Neurol. 10, 59 (2010).
Tao, Q. Q. et al. Clinical and genetic characteristics of Chinese patients with cerebrotendinous xanthomatosis. Orphanet J. Rare Dis. 14, 282 (2019).
Davis, D. L. et al. Dynamics of sphingolipids and the serine palmitoyltransferase complex in rat oligodendrocytes during myelination. J. Lipid Res. 61, 505–522 (2020).
Wang, J. et al. Myelin lipid abnormalities in the aspartoacylase-deficient tremor rat. Neurochem Res. 34, 138–148 (2009).
Pant, D. C. et al. Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy. J. Clin. Invest. 129, 1240–1256 (2019).
Bieberich, E. There is more to a lipid than just being a fat: sphingolipid-guided differentiation of oligodendroglial lineage from embryonic stem cells. Neurochem Res. 36, 1601–1611 (2011).
Marin-Valencia, I., Roe, C. R. & Pascual, J. M. Pyruvate carboxylase deficiency: mechanisms, mimics and anaplerosis. Mol. Genet. Metab. 101, 9–17 (2010).
Plemel, J. R., Liu, W. Q. & Yong, V. W. Remyelination therapies: a new direction and challenge in multiple sclerosis. Nat. Rev. Drug Discov. 16, 617–634 (2017).
Ghorbani, S. & Yong, V. W. The extracellular matrix as modifier of neuroinflammation and remyelination in multiple sclerosis. Brain 144, 1958–1973 (2021).
Lloyd, A. F. & Miron, V. E. The pro-remyelination properties of microglia in the central nervous system. Nat. Rev. Neurol. 15, 447–458 (2019).
Miron, V. E. Microglia-driven regulation of oligodendrocyte lineage cells, myelination, and remyelination. J. Leukoc. Biol. 101, 1103–1108 (2017).
Zhou, L. et al. Gab1 mediates PDGF signaling and is essential to oligodendrocyte differentiation and CNS myelination. Elife 9, https://doi.org/10.7554/eLife.52056 (2020).
Watzlawik, J. O., Warrington, A. E. & Rodriguez, M. PDGF is required for remyelination-promoting IgM stimulation of oligodendrocyte progenitor cell proliferation. PLoS ONE 8, e55149 (2013).
Medved, J. et al. Novel guanidine compounds inhibit platelet-derived growth factor receptor alpha transcription and oligodendrocyte precursor cell proliferation. Glia 69, 792–811 (2021).
Yao, Z. F. et al. Transplantation of PDGF-AA-overexpressing oligodendrocyte precursor cells promotes recovery in rat following spinal cord injury. Front. Cell Neurosci. 11, 79 (2017).
Sherafat, A., Pfeiffer, F., Reiss, A. M., Wood, W. M. & Nishiyama, A. Microglial neuropilin-1 promotes oligodendrocyte expansion during development and remyelination by trans-activating platelet-derived growth factor receptor. Nat. Commun. 12, 2265 (2021).
Younsi, A. et al. Three growth factors induce proliferation and differentiation of neural precursor cells in vitro and support cell-transplantation after spinal cord injury in vivo. Stem Cells Int. 2020, 5674921 (2020).
Cardona, H. J., Somasundaram, A., Crabtree, D. M., Gadd, S. L. & Becher, O. J. Prenatal overexpression of platelet-derived growth factor receptor A results in central nervous system hypomyelination. Brain Behav. 11, e2332 (2021).
Furusho, M., Dupree, J. L., Nave, K. A. & Bansal, R. Fibroblast growth factor receptor signaling in oligodendrocytes regulates myelin sheath thickness. J. Neurosci. 32, 6631–6641 (2012).
Furusho, M., Ishii, A. & Bansal, R. Signaling by FGF receptor 2, not FGF receptor 1, regulates myelin thickness through activation of ERK1/2-MAPK, which promotes mTORC1 activity in an Akt-independent manner. J. Neurosci. 37, 2931–2946 (2017).
Rajendran, R., Giraldo-Velasquez, M., Stadelmann, C. & Berghoff, M. Oligodendroglial fibroblast growth factor receptor 1 gene targeting protects mice from experimental autoimmune encephalomyelitis through ERK/AKT phosphorylation. Brain Pathol. 28, 212–224 (2018).
Thummler, K. et al. Polarizing receptor activation dissociates fibroblast growth factor 2 mediated inhibition of myelination from its neuroprotective potential. Acta Neuropathol. Commun. 7, 212 (2019).
Fortin, D., Rom, E., Sun, H., Yayon, A. & Bansal, R. Distinct fibroblast growth factor (FGF)/FGF receptor signaling pairs initiate diverse cellular responses in the oligodendrocyte lineage. J. Neurosci. 25, 7470–7479 (2005).
Butt, A. M. & Dinsdale, J. Fibroblast growth factor 2 induces loss of adult oligodendrocytes and myelin in vivo. Exp. Neurol. 192, 125–133 (2005).
de Jong, J. M., Wang, P., Oomkens, M. & Baron, W. Remodeling of the interstitial extracellular matrix in white matter multiple sclerosis lesions: Implications for remyelination failure. J. Neurosci. Res. 98, 1370–1397 (2020).
Malekzadeh, A. et al. Plasma proteome in multiple sclerosis disease progression. Ann. Clin. Transl. Neurol. 6, 1582–1594 (2019).
Buttery, P. C. & ffrench-Constant, C. Laminin-2/integrin interactions enhance myelin membrane formation by oligodendrocytes. Mol. Cell Neurosci. 14, 199–212 (1999).
Colognato, H. et al. CNS integrins switch growth factor signalling to promote target-dependent survival. Nat. Cell Biol. 4, 833–841 (2002).
Laursen, L. S., Chan, C. W. & Ffrench-Constant, C. Translation of myelin basic protein mRNA in oligodendrocytes is regulated by integrin activation and hnRNP-K. J. Cell Biol. 192, 797–811 (2011).
Camara, J. et al. Integrin-mediated axoglial interactions initiate myelination in the central nervous system. J. Cell Biol. 185, 699–712 (2009).
Decker, L. & ffrench-Constant, C. Lipid rafts and integrin activation regulate oligodendrocyte survival. J. Neurosci. 24, 3816–3825 (2004).
Relvas, J. B. et al. Expression of dominant-negative and chimeric subunits reveals an essential role for beta1 integrin during myelination. Curr. Biol. 11, 1039–1043 (2001).
Stoffels, J. M. et al. Fibronectin aggregation in multiple sclerosis lesions impairs remyelination. Brain 136, 116–131 (2013).
Back, S. A. et al. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat. Med. 11, 966–972 (2005).
Bugiani, M. et al. Hyaluronan accumulation and arrested oligodendrocyte progenitor maturation in vanishing white matter disease. Brain 136, 209–222 (2013).
Sloane, J. A. et al. Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. Proc. Natl Acad. Sci. USA 107, 11555–11560 (2010).
Zhang, Q. et al. High level of serum and cerebrospinal fluid of heparan sulfate and hyaluronic acid might be a biomarker of severity of neuromyelitis optica. Front. Immunol. 12, 705536 (2021).
Jagielska, A. et al. Mechanical strain promotes oligodendrocyte differentiation by global changes of gene expression. Front. Cell Neurosci. 11, 93 (2017).
Urbanski, M. M., Brendel, M. B. & Melendez-Vasquez, C. V. Acute and chronic demyelinated CNS lesions exhibit opposite elastic properties. Sci. Rep. 9, 999 (2019).
Mozafari, S. et al. Multiple sclerosis iPS-derived oligodendroglia conserve their properties to functionally interact with axons and glia in vivo. Sci. Adv. 6, https://doi.org/10.1126/sciadv.abc6983 (2020).
Starost, L. et al. Extrinsic immune cell-derived, but not intrinsic oligodendroglial factors contribute to oligodendroglial differentiation block in multiple sclerosis. Acta Neuropathol. 140, 715–736 (2020).
Yamasaki, R. et al. Differential roles of microglia and monocytes in the inflamed central nervous system. J. Exp. Med. 211, 1533–1549 (2014).
Ajami, B., Bennett, J. L., Krieger, C., McNagny, K. M. & Rossi, F. M. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat. Neurosci. 14, 1142–1149 (2011).
Marzan, D. E. et al. Activated microglia drive demyelination via CSF1R signaling. Glia 69, 1583–1604 (2021).
Clark, I. C. et al. Barcoded viral tracing of single-cell interactions in central nervous system inflammation. Science 372, https://doi.org/10.1126/science.abf1230 (2021).
Hughes, A. N. & Appel, B. Microglia phagocytose myelin sheaths to modify developmental myelination. Nat. Neurosci. 23, 1055–1066 (2020).
Li, J. et al. Tumor necrosis factor alpha mediates lipopolysaccharide-induced microglial toxicity to developing oligodendrocytes when astrocytes are present. J. Neurosci. 28, 5321–5330 (2008).
Argaw, A. T. et al. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J. Clin. Invest. 122, 2454–2468 (2012).
Kim, R. Y. et al. Astrocyte CCL2 sustains immune cell infiltration in chronic experimental autoimmune encephalomyelitis. J. Neuroimmunol. 274, 53–61 (2014).
Meares, G. P., Ma, X., Qin, H. & Benveniste, E. N. Regulation of CCL20 expression in astrocytes by IL-6 and IL-17. Glia 60, 771–781 (2012).
Nitsch, L. et al. Astrocyte-specific expression of interleukin 23 leads to an aggravated phenotype and enhanced inflammatory response with B cell accumulation in the EAE model. J. Neuroinflammation 18, 101 (2021).
Hridi, S. U. et al. Increased levels of IL-16 in the central nervous system during neuroinflammation are associated with infiltrating immune cells and resident glial cells. Biology 10, https://doi.org/10.3390/biology10060472 (2021).
Moore, C. S. et al. Direct and indirect effects of immune and central nervous system-resident cells on human oligodendrocyte progenitor cell differentiation. J. Immunol. 194, 761–772 (2015).
Sanmarco, L. M. et al. Gut-licensed IFNgamma(+) NK cells drive LAMP1(+)TRAIL(+) anti-inflammatory astrocytes. Nature 590, 473–479 (2021).
Vanderlocht, J. et al. Leukemia inhibitory factor is produced by myelin-reactive T cells from multiple sclerosis patients and protects against tumor necrosis factor-alpha-induced oligodendrocyte apoptosis. J. Neurosci. Res. 83, 763–774 (2006).
Molina-Gonzalez, I. & Miron, V. E. Astrocytes in myelination and remyelination. Neurosci. Lett. 713, 134532 (2019).
Dillenburg, A. et al. Activin receptors regulate the oligodendrocyte lineage in health and disease. Acta Neuropathol. 135, 887–906 (2018).
Lubetzki, C., Zalc, B., Williams, A., Stadelmann, C. & Stankoff, B. Remyelination in multiple sclerosis: from basic science to clinical translation. Lancet Neurol. 19, 678–688 (2020).
Stangel, M., Kuhlmann, T., Matthews, P. M. & Kilpatrick, T. J. Achievements and obstacles of remyelinating therapies in multiple sclerosis. Nat. Rev. Neurol. 13, 742–754 (2017).
Duncan, I. D. et al. The adult oligodendrocyte can participate in remyelination. Proc. Natl Acad. Sci. USA 115, E11807–E11816 (2018).
Bacmeister, C. M. et al. Motor learning promotes remyelination via new and surviving oligodendrocytes. Nat. Neurosci. 23, 819–831 (2020). This was the first study demonstrating that mature oligodendrocytes which survive after demyelinating injury can regenerate processes to remyelinate, although this is a rare occurance.
Neely, S. A. et al. New oligodendrocytes exhibit more abundant and accurate myelin regeneration than those that survive demyelination. Nat. Neurosci. 25, 415–420 (2022). This study revealed that mature oligodendrocytes which contribute to remyelination do so inefficiently and poorly, misdirecting their myelin to neuronal cell bodies.
Yeung, M. S. Y. et al. Dynamics of oligodendrocyte generation in multiple sclerosis. Nature 566, 538–542 (2019). This study measured integration of 14C derived from nuclear testing in genomic DNA to assess the dynamics of oligodendrocyte generation in multiple sclerosis brain and found that most cells within remyelinating lesions were ‘old’, suggesting that surviving mature oligodendrocyes may have contributed to remyelination.
Shen, K. et al. Multiple sclerosis risk gene Mertk is required for microglial activation and subsequent remyelination. Cell Rep. 34, 108835 (2021).
Zhou, Y. et al. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease. Nat. Med. 26, 131–142 (2020).
Kirby, L. & Castelo-Branco, G. Crossing boundaries: Interplay between the immune system and oligodendrocyte lineage cells. Semin Cell Dev. Biol. 116, 45–52 (2021).
Liu, F., Vidarsson, L., Winter, J. D., Tran, H. & Kassner, A. Sex differences in the human corpus callosum microstructure: a combined T2 myelin-water and diffusion tensor magnetic resonance imaging study. Brain Res. 1343, 37–45 (2010).
Darling, J. S. & Daniel, J. M. Pubertal hormones mediate sex differences in levels of myelin basic protein in the orbitofrontal cortex of adult rats. Neuroscience 406, 487–495 (2019).
Raffaele, S., Boccazzi, M. & Fumagalli, M. Oligodendrocyte dysfunction in amyotrophic lateral sclerosis: mechanisms and therapeutic perspectives. Cells 10, https://doi.org/10.3390/cells10030565 (2021).
Ferrari Bardile, C. et al. Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease. Proc. Natl Acad. Sci. USA 116, 9622–9627 (2019).